Nicolae Bacalbasa1, Irina Balescu2, Simona Dima3, Vladislav Brasoveanu3, Irinel Popescu4. 1. Carol Davila U.M.F., Bucharest, Romania irinel.popescu220@gmail.com nicolae_bacalbasa@yahoo.ro nicolaebacalbasa@gmail.com. 2. Ponderas Hospital, Bucharest, Romania. 3. Dan Setlacec Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania. 4. Carol Davila U.M.F., Bucharest, Romania Dan Setlacec Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania irinel.popescu220@gmail.com nicolae_bacalbasa@yahoo.ro nicolaebacalbasa@gmail.com.
Abstract
AIM: To (i) determine prognostic factors after initial surgery for uterine leiomyosarcomas (LMS) and their recurrence and (ii) assess the effectiveness of re-resections. PATIENTS AND METHODS: All cases that underwent surgery for uterine leiomyosarcomas at the Fundeni Clinical Institute, Bucharest between 2002 and 2013 were reviewed. Twenty-six patients with primary uterine leiomyosarcomas were introduced in our study. Sixteen of them were re-addressed to the same hospital for recurrence. RESULTS: At the moment of initial surgery the most important prognostic factors were age <60 years, International Federation of Gynecology and Obstetrics (FIGO) stage I, tumor dimension <15 cm and mitotic index <15/10 high-power fields (HPF). The five-year overall survival was 40%. Sixteen patients were re-operated for recurrence; the most important prognostic factors being a late recurrence (>12 months) and initial FIGO stage I. The five-year overall survival was 12.5%. CONCLUSION: Uterine leiomyosarcoma is an aggressive malignancy with a high rate of recurrence. In selected cases surgery may be attempted for re-recurrence. Copyright
AIM: To (i) determine prognostic factors after initial surgery for uterine leiomyosarcomas (LMS) and their recurrence and (ii) assess the effectiveness of re-resections. PATIENTS AND METHODS: All cases that underwent surgery for uterine leiomyosarcomas at the Fundeni Clinical Institute, Bucharest between 2002 and 2013 were reviewed. Twenty-six patients with primary uterine leiomyosarcomas were introduced in our study. Sixteen of them were re-addressed to the same hospital for recurrence. RESULTS: At the moment of initial surgery the most important prognostic factors were age <60 years, International Federation of Gynecology and Obstetrics (FIGO) stage I, tumor dimension <15 cm and mitotic index <15/10 high-power fields (HPF). The five-year overall survival was 40%. Sixteen patients were re-operated for recurrence; the most important prognostic factors being a late recurrence (>12 months) and initial FIGO stage I. The five-year overall survival was 12.5%. CONCLUSION: Uterine leiomyosarcoma is an aggressive malignancy with a high rate of recurrence. In selected cases surgery may be attempted for re-recurrence. Copyright